38.80 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||38.07 x 1100|
|Ask||38.50 x 1000|
|Day's Range||37.56 - 42.49|
|52 Week Range||19.50 - 47.50|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.33|
Biopharmaceutical company Cortexyme is currently in a clinical trial stage, researching what they believe is a new way to treat the cause of Alzheimer's disease and other degenerative diseases. Cortexyme Co-Founder, Chairperson and CEO Casey Lynch sits down with Yahoo Finance's Adam Shapiro, Julie Hyman, and Scott Gamm to discuss.
Cortexyme, Inc. (CRTX), today announced that its work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases will be discussed in two research abstracts at the Alzheimer’s Association International Conference® 2019 (AAIC®). The conference, which is the largest international meeting dedicated to advancing dementia science, will be held July 14-18, 2019 in Los Angeles.
About 15 percent of the companies in the U.S. that have gone public so far in 2019 are led by female CEOs, the highest number in at last six years and triple the number of woman-run companies listed in the Russell 2000.
The average return on U.S. IPOs in the second quarter was 30 percent, a mark hit or exceeded by 11 of the Bay Area's 23 new public companies so far this year.
Cortexyme, Inc. (CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced four new additions to its Clinical Advisory Board (CAB). Jeffrey Cummings, M.D., Sc.D., David Hosford M.D., Ph.D., Lon Schneider, M.D., M.S., and Pierre N. Tariot, M.D. join the CAB with deep and diverse experience in central nervous system (CNS) drug development.
Cortexyme, Inc. (CRTX) today announced that Casey Lynch, the company’s chief executive officer, chairman, and co-founder, will present at a National Academies of Science, Engineering, and Medicine workshop on the growing understanding of the relationship between pathogens and chronic disease this week. Ms. Lynch will provide an overview of Cortexyme’s work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases during “Breaking Down Silos: The Convergence of Infectious Diseases and Noncommunicable Diseases,” which will be held June 11-12 in New York. In her remarks, Ms. Lynch will review the scientific rationale and data supporting a key role for Porphyromonas gingivalis in the development of Alzheimer’s disease, based on the identification of the bacteria in the brain of Alzheimer’s patients and its ability to cause neurodegeneration, inflammation, and other pathology associated with Alzheimer’s in animal models.
Cortexyme, Inc. (CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions. In addition, Cortexyme has granted the underwriters a 30-day option to purchase up to an additional 661,800 shares at the initial public offering price, less the underwriting discounts and commissions.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Milestone Pharmaceuticals Inc. (MIST) will issue 5 million shares between ...